Scarica l'app Stockscreener
4.52
82.26%
2.04
Dopo l'orario di chiusura:
3.81
-0.71
-15.71%
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed Inc. Files Form 8-K with SEC – Company Information, Address, and Common Stock Details - Minichart
Why did CRVO stock crash 22% in pre-market trading today? - MSN
CervoMed Posts Updated Investor Presentation and Business Overview - TipRanks
CervoMed director Joshua Boger acquires $2.99m in common stock By Investing.com - Investing.com India
Cervomed Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing - marketscreener.com
CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake - Stock Titan
Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal - Stock Titan
CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings - Stock Titan
CRVO: Advancing neflamapimod to phase III in DLB, with strategic partnership and strong clinical data - TradingView
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - 富途牛牛
CervoMed Insiders Lose Out As Stock Sinks To US$2.45 - Yahoo Finance
CervoMed Inc. (CRVO) Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Progress ContinuesEPS Revision Trend - newsline.com
CervoMed Inc. (CRVO) Surges 8.44%: Testing Key Resistance at $2.56TWAP Entry - newsline.com
CervoMed Inc. (CRVO) Gains 8.4%: Support Holds as Stock Approaches Key ResistanceBearish Sentiment - newsline.com
CervoMed (CRVO) director Frank Zavrl receives grant of 8,150 stock options - Stock Titan
CervoMed (CRVO) awards 8,150 stock options to new board director - Stock Titan
CervoMed (CRVO) grants director David Quigley options on 8,150 shares - Stock Titan
[Form 4] CervoMed Inc. Insider Trading Activity - Stock Titan
CervoMed (CRVO) director receives options for 8,150 shares at $2.91 strike - Stock Titan
CervoMed (CRVO) director Sylvie Gregoire receives 8,150-share stock option award - Stock Titan
CervoMed (CRVO) director and 10% owner granted 8,150 stock options at $2.91 - Stock Titan
CervoMed (CRVO) director and CEO’s spouse granted 8,150 stock options - Stock Titan
CRVO Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Development PhaseEarnings Call Q&A - newsline.com
CervoMed (CRVO) Secures $10.5M from Private Placement - GuruFocus
CervoMed (CRVO) Secures $10.5 Million from Private Placement - GuruFocus
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today? - Asianet Newsable
CervoMed stock falls 15% after $10.5M financing announced By Investing.com - Investing.com South Africa
CervoMed stock falls 15% after $10.5M financing announced - Investing.com
CervoMed Announces Private Placement to Advance Neurology Pipeline - TipRanks
CervoMed raises $10.5 million in private placement financing - Investing.com
CervoMed : Corporate Presentation (54c99e) - marketscreener.com
CervoMed raises $10.5 million in private placement financing By Investing.com - Investing.com Canada
CervoMed Secures $10.5M Private Placement of Units With Warrants; Up to $21.7M More Possible - TradingView
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies - The Manila Times
CervoMed (NASDAQ: CRVO) secures $10.5M financing to extend cash runway into 2027 - Stock Titan
CervoMed shareholders approve board elections and key proposals at annual meeting By Investing.com - Investing.com South Africa
CervoMed Shareholders Back Board, Pay and Incentive Plan - TipRanks
CervoMed shareholders approve board elections and key proposals at annual meeting - Investing.com
CervoMed (NASDAQ: CRVO) logs 67% turnout, backs 2026 proposals - Stock Titan
CRVO Q1 2026 Earnings: Wider-than-Expected Loss on No Revenue; Stock Slightly DownEarnings Decline Risk - newsline.com
CRVO Q1 2026 Earnings: EPS Misses Estimates as Clinical‑Stage Biotech Maintains R&D FocusPositive Surprise Momentum - newsline.com
CervoMed Inc. (CRVO) Edges Lower as Stock Tests Support Near $3.00Trend Following Picks - The Legal Advocate
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CervoMed Inc. (CRVO) Hovers Near Key Support After Marginal DeclineHedge Fund Exposure - newsline.com
CRVO Q1 2026 Earnings: EPS Misses EstimatesEarnings Revision Report - The Legal Advocate
CRVO Q1 2026 Earnings: EPS Miss Reflects Continued Clinical InvestmentReal Trader Network - Newser
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes - Bez Kabli
CervoMed Inc. (CRVO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineNet Profit Margin - Newser
CRVO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Company Reports No RevenueTrough Earnings Signal - The Legal Advocate
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):